Atea Pharmaceuticals (AVIR) EBT: 2019-2024
Historic EBT for Atea Pharmaceuticals (AVIR) over the last 6 years, with Dec 2024 value amounting to -$167.5 million.
- Atea Pharmaceuticals' EBT fell 128.30% to -$34.3 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$119.5 million, marking a year-over-year decrease of 186.22%. This contributed to the annual value of -$167.5 million for FY2024, which is 24.10% down from last year.
- Atea Pharmaceuticals' EBT amounted to -$167.5 million in FY2024, which was down 24.10% from -$134.9 million recorded in FY2023.
- Atea Pharmaceuticals' 5-year EBT high stood at $138.6 million for FY2021, and its period low was -$167.5 million during FY2024.
- Over the past 3 years, Atea Pharmaceuticals' median EBT value was -$134.9 million (recorded in 2023), while the average stood at -$140.6 million.
- In the last 5 years, Atea Pharmaceuticals' EBT soared by 1,366.01% in 2021 and then tumbled by 186.22% in 2022.
- Over the past 5 years, Atea Pharmaceuticals' EBT (Yearly) stood at -$10.9 million in 2020, then spiked by 1,366.01% to $138.6 million in 2021, then slumped by 186.22% to -$119.5 million in 2022, then dropped by 12.92% to -$134.9 million in 2023, then dropped by 24.10% to -$167.5 million in 2024.